Lv51
1315 积分 2021-12-23 加入
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
26天前
已完结
Resmetirom: First Approval
26天前
已完结
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
26天前
已完结
绿原酸的研究进展
2个月前
已完结
绿原酸抗病毒研究进展
2个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
3个月前
已完结
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
7个月前
已关闭
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
7个月前
已关闭
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
8个月前
已完结
嵌入式生物信息采集系统的研究
8个月前
已完结
皖公网安备34019202002308
